Yujuan Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yujuan Zhao has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Wendi Huang
Department of Neonatology, Xi’an Children’s Hospital, Xi’an City, China
2 shared publicationsYing Ma
Department of Neonatology, Xi’an Children’s Hospital, Xi’an City, China
2 shared publicationsFengyu Che
Shaanxi Institute for Pediatric Diseases, Xi’an Children’s Hospital, Xi’an, China
1 shared publicationHaibin Wu
Shaanxi Institute for Pediatric Diseases, Xi’an Children’s Hospital, Xi’an, China
1 shared publication- Han Xia
Department of Scientific Affairs, Hugobiotech Co., Ltd., Beijing, China
1 shared publication Jiakai Wei
Xi’an Children’s Hospital, Xi’an, China
1 shared publication
Latest Publications
- 6 November 2023
- Published by Springer Nature in neurogenetics
- Vol. 25 (1) , 27-31
Lethal variant in the C2A domain may cause severe SYT1-associated neurodevelopmental disorder in the newborns
Synaptotagmin-1 (SYT1) plays a pivotal role in regulating presynaptic processes, including neurotransmitter release. SYT1 variants perturb synaptic vesicle endocytosis and exocytosis, resulting in a series of neurodevelopmental disorders defined as Baker-Gordon syndrome. Herein, we report the case of a newborn with dysmorphic facial appearance, severe hypotonia, poor feeding, gastroesophageal reflux, and an inability to eat and breathe, diagnosed with Baker–Gordon syndrome. A retrospective search was performed on a newborn with Baker-Gordon syndrome. Medical charts were reviewed, with focus on the clinical presentation, diagnostic process, and treatment outcomes. Whole-genome high-throughput DNA sequencing was performed to identify genetic variants. Whole-exome sequencing identified the likely pathogenic variant as SYT1 C.551 T > C(p.V184A). Sanger sequencing results indicated that this variant was a de novo mutation in a conservative site located in the C2A domain of the protein. The patient died at 57 days old because of severe feeding and breathing problems. Our findings of a novel lethal variant in the C2A domain of SYT1 in the youngest patient diagnosed infantile Baker-Gordon syndrome who presented with the most severe hypotonia reported to date expands the spectrum of SYT1- associated neurodevelopmental disorders.
- 6 November 2023
- Published by Springer Nature in neurogenetics
- Vol. 25 (1) , 27-31
Lethal variant in the C2A domain may cause severe SYT1-associated neurodevelopmental disorder in the newborns
Synaptotagmin-1 (SYT1) plays a pivotal role in regulating presynaptic processes, including neurotransmitter release. SYT1 variants perturb synaptic vesicle endocytosis and exocytosis, resulting in a series of neurodevelopmental disorders defined as Baker-Gordon syndrome. Herein, we report the case of a newborn with dysmorphic facial appearance, severe hypotonia, poor feeding, gastroesophageal reflux, and an inability to eat and breathe, diagnosed with Baker–Gordon syndrome. A retrospective search was performed on a newborn with Baker-Gordon syndrome. Medical charts were reviewed, with focus on the clinical presentation, diagnostic process, and treatment outcomes. Whole-genome high-throughput DNA sequencing was performed to identify genetic variants. Whole-exome sequencing identified the likely pathogenic variant as SYT1 C.551 T > C(p.V184A). Sanger sequencing results indicated that this variant was a de novo mutation in a conservative site located in the C2A domain of the protein. The patient died at 57 days old because of severe feeding and breathing problems. Our findings of a novel lethal variant in the C2A domain of SYT1 in the youngest patient diagnosed infantile Baker-Gordon syndrome who presented with the most severe hypotonia reported to date expands the spectrum of SYT1- associated neurodevelopmental disorders.
- Open Access
- 21 December 2022
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 10 (6) , e0119522
Metagenomic Next-Generation Sequencing for the Diagnosis of Neonatal Infectious Diseases
To the best of our knowledge, this is the first report on evaluating the performance of mNGS using cfDNA and RNA from body fluid and blood samples for diagnosing neonatal infections. mNGS of RNA and cfDNA can achieve the unbiased detection and identification of trace pathogens from different kinds of neonatal body fluid and blood samples with a high total coincidence rate (226/331; 68.3%) against final clinical diagnoses by sample. The best timing for mNGS detection in neonatal infections ranged from 1 to 3 days, rather than 0 days, after the start of continuous antimicrobial therapy.
- 21 December 2022
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 10 (6) , e0119522
Open AccessMetagenomic Next-Generation Sequencing for the Diagnosis of Neonatal Infectious Diseases
To the best of our knowledge, this is the first report on evaluating the performance of mNGS using cfDNA and RNA from body fluid and blood samples for diagnosing neonatal infections. mNGS of RNA and cfDNA can achieve the unbiased detection and identification of trace pathogens from different kinds of neonatal body fluid and blood samples with a high total coincidence rate (226/331; 68.3%) against final clinical diagnoses by sample. The best timing for mNGS detection in neonatal infections ranged from 1 to 3 days, rather than 0 days, after the start of continuous antimicrobial therapy.